Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
- Conditions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 50000000
- Registration Number
- NCT04958954
- Locations
- 🇺🇸
Aetion Inc., New York, New York, United States
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
- Conditions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04958304
- Locations
- 🇺🇸
IQVIA Call Center for United States and Canada, Durham, North Carolina, United States
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 885
- Registration Number
- NCT04956575
- Locations
- 🇺🇸
Research Centers of America - ERGG - PPDS, Hollywood, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC - Phoenix, Tempe, Arizona, United States
🇺🇸Meridian Clinical Research (Savannah Georgia) - Platinum - PPDS, Savannah, Georgia, United States
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 8538
- Registration Number
- NCT04941144
- Locations
- 🇯🇵
Moderna selected site, Tokyo, Japan
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 5404
- Registration Number
- NCT04927065
- Locations
- 🇺🇸
Research Centers of America, Hollywood, Florida, United States
🇺🇸Jacksonville Center For Clinical Research, Jacksonville, Florida, United States
🇺🇸Meridian Clinical Research (Iowa), Sioux City, Iowa, United States
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 808
- Registration Number
- NCT04917861
- Locations
- 🇵🇷
Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico
🇵🇷Ponce Medical School Foundation, Inc., Ponce, Puerto Rico
🇵🇷Carribean Medical Research, San Juan, Puerto Rico
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04916431
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia
A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04899310
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT04860297
- Locations
- 🇺🇸
Aventiv Research Inc, Mesa, Arizona, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04813796
- Locations
- 🇺🇸
Synexus Clinical Research US Phoenix Southeast, Inc., Chandler, Arizona, United States
🇺🇸Optimal Research San Diego, LLC, San Diego, California, United States
🇺🇸Optimal Research Illinois, LLC, Peoria, Illinois, United States